The Knowledge Hub for Medical Imaging Professionals: Transforming Radiology with Structured Reporting, Data-Driven Approaches and Multicentric Research

Access breakthrough research, innovative case studies and collaborative projects advancing radiology worldwide. Dive into our activities and product updates, and learn who we are as a company and as a team.

Screenshot of a prostate lesion in mint Lesion

Streamline Prostate Cancer Screenings with Prostate.Carcinoma.ai in mint Lesion

The Prostate.Carcinoma.ai plug-in, developed by our partner FUSE-AI, is a powerful addition to mint Lesion, designed specifically to enhance prostate cancer screenings. This advanced solution leverages artificial intelligence to automate and accelerate prostate MR evaluations based on the PI-RADS 2.1 guidelines, transforming the workflow and precision for radiologists.

At the click of a button, Prostate.Carcinoma.ai performs full segmentation of the prostate and its anatomical zones, and detects and segments potentially malignant lesions. mint Lesion maps each finding onto the standardized prostate lesion scheme, eliminating the need for time-consuming manual lesion annotation and drawing.

Radiologists maintain full control over the AI-generated results, with the ability to review, reject, modify, or add new findings to ensure accuracy. Based on these inputs, mint Lesion automatically calculates the PI-RADS score, delivering a comprehensive and structured report.

mint Lesion also enables longitudinal tracking of prostate lesions for MRI-based active surveillance. Radiologists can easily monitor changes in lesions over time, supporting informed decision-making for patient management and enhancing the continuity of care.

Learn more on our partner page.

Related Resources

Related Resources

Hands holding a glass lung to evoke image of lung cancer

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing…

Image shows graphic related to study's research on iRECIST and RECIST

University Hospital Cologne: Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

A retrospective study conducted at University Hospital Cologne compared two criteria for assessing therapeutic response to immunotherapy: iRECIST and…

Doctors holding up puzzle pieces; representing working together

Developing Standardized Reporting Templates for Sarcomas: Insights from Prof. Dr. Wolfgang Kunz

Sarcomas are a rare and heterogeneous group of malignant tumors that pose significant challenges in both diagnosis and treatment. Within the framework…